Cost Curve

White House Claims a ‘Significant’ Number of Companies Have Elected to Join MFN-in-Medicaid Model

And HHS is taking the next step in transitioning toward a 340B ‘rebate model’

Brian Reid

A Key Deadline for Companies Seeking MFN Deals Has Arrived

And Pfizer’s CEO sends a letter to Germany’s leader: ”We are ​reviewing ... certain planned investments in Germany”

Brian Reid

Politico Says the U.S. and Germany Are In ‘Secret Talks’ About MFN

And PCMA releases a document that is a master class in finger-pointing

Brian Reid

CMS Will Need to Bridge Beyond the ‘Bridge’ Demo to Preserve Long-Term Access to Obesity Meds in Medicare

And I have the numbers on TrumpRx’s web visit numbers for May

Brian Reid

It’s All Obesity Today: Drama at ADA, Pricing Implications for Pfizer’s Med, and WSJ on Shrinking Employer Coverage

Plus: ‘Why would you threaten 50% of your revenue if you think you cannot get a reasonable price in the UK or France?’

Brian Reid

Supreme Court Addresses ‘Skinny Labeling’ for Generic Drugs

And Pfizer’s Impact Report is out, detailing how the company’s portfolio-wide net price shifted in 2025

Brian Reid

An Apex Grab Bag on Value-Based Insurance, Investments in Europe, and Ongoing 340B Battles

Brian Reid

TrumpRx Traffic Numbers, Touted by Oz, Appear to Be Falling

And the top of the Fortune 500 list is a who’s-who companies profiting from 340B

Brian Reid

Lilly Says Smaller Clinics Have No Problems With 340B Transparency Acts, Even as Big, Profitmaxxing Hospitals Object

Brian Reid